Search

everythinglearnresearchcommunity

for

Search:↓

Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.

The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.

Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.

Pranic meditation significantly improved mental health and quality of life for breast cancer survivors.

Different types of persistent hair loss after chemotherapy respond differently to treatments.

Breast cancer survivors often face body image and sexual health issues, needing ongoing support and open communication with healthcare providers.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Oral minoxidil may help hair regrowth in female cancer survivors.

Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.

Permanent hair loss from chemotherapy significantly impacts patients' mental health and social life, highlighting the need for better patient education and support.

Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.

Long-term estrogen therapy in postmenopausal women can improve certain health markers, hair loss is common regardless of hormone use, stopping estrogen doesn't increase breast cancer risk, smoking does, and a balanced BMI is linked to lower mortality.

Scalp cooling is the only FDA-approved method to prevent hair loss from chemotherapy, but other treatments like minoxidil and PRP are being tested.

The review recommends hormone replacement therapy for women with premature ovarian insufficiency to manage symptoms and protect health, with specific approaches for different groups.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

Reproductive hormones play a crucial role in breast cancer development and treatment challenges.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

Different types of fibroblasts play specific roles in wound healing and cancer, which could help improve treatments.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.

Better awareness of chemotherapy's side effects improves self-care.

Oncologists should better understand the unique impact of hair loss on Black breast cancer patients to offer more compassionate care.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Xiaoaiping reduces chemotherapy side effects and improves quality of life for breast cancer patients.